Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say

Core Insights - Jazz Pharmaceuticals reported revenue of $1.05 billion for the quarter ended June 2025, reflecting a year-over-year increase of 2.1% but a slight miss of 0.26% against the Zacks Consensus Estimate [1] - The company experienced a significant decline in EPS, reporting -$8.25 compared to $5.30 in the same quarter last year, resulting in an EPS surprise of -34.8% against the consensus estimate of -$6.12 [1] Revenue Breakdown - Total revenues from royalties and contract revenues were $60.14 million, exceeding the average estimate of $55.53 million by analysts [4] - Product sales, net, amounted to $985.57 million, slightly below the average estimate of $999.45 million, with a year-over-year change of +2.2% [4] - Neuroscience total revenues reached $707.02 million, which was lower than the estimated $716.27 million, but represented a year-over-year increase of +3.3% [4] - Oncology total revenues were $274.15 million, marginally below the average estimate of $274.32 million, reflecting a year-over-year decrease of -1.1% [4] - Specific product performance included: - Rylaze/Enrylaze: $100.66 million, below the estimate of $105.31 million, a -6.7% change year-over-year [4] - Oxybate (Xywav & Xyrem): $450.67 million, exceeding the estimate of $440.11 million, with a +4.7% change year-over-year [4] - Sativex: $4.62 million, below the estimate of $5.63 million, a -27.7% change year-over-year [4] - Oxybate - Xyrem: $35.35 million, slightly above the estimate of $34.64 million, a -43.2% change year-over-year [4] - Defitelio/defibrotide: $48.11 million, above the estimate of $47.83 million, a +5.9% change year-over-year [4] - Vyxeos: $44.85 million, exceeding the estimate of $41.48 million, a +4.3% change year-over-year [4] - Zepzelca: $74.54 million, below the estimate of $77.82 million, an -8% change year-over-year [4] - Oxybate - Xywav: $415.32 million, above the estimate of $405.49 million, a +12.7% change year-over-year [4] Stock Performance - Jazz Pharmaceuticals' shares have returned +7.9% over the past month, outperforming the Zacks S&P 500 composite, which changed by +1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]